Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 5, pp 353–358 | Cite as

Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice

  • Yuchi Iino
  • Yoshiki Takai
  • Tatsumasa Ando
  • Noritaka Sugamata
  • Michio Maemura
  • Takeshi Takeo
  • Susumu Ohwada
  • Yasuo Morishita
Original Articles Torernitene, MCF-7 tumor, Athymic Mice


Toremifene given in different sizes of silastic capsules was used to treat MCF-7 tumors in athmic mice. Toremifene inhibited the estradiol-stimulated growth of MCF-7 tumors in athymic mice. Average serum concentrations of toremifene obtained using a sustained-release preparation of the drug (in 0.5-, 1.0-, and 2.0-cm silastic capsules) increased gradually in a capsule-size-dependent fashion. Much higher levels of toremifene orN-demethyltoremifene were detected in tumors(target tissues of estrogen) as compared with muscles (non-target tissues of estrogen). The concentration of toremifene in serum (i.e., 10–30 ng ml−1) was sufficient to inhibit the estrogen-stimulated growth of MCF-7 tumors at physiological (i.e., 200–400 pg ml−1) serum estradiol concentrations in premenopausal women. No significant difference in estrogen receptor (ER) levels was found between the estradiol-alone group and the toremifene-treated groups. However, the ER levels in the toremifene-alone group and the no-treatment group (no toremifene or estradiol) tended to increase as compared with the estradiol-alone group. Toremifene blocked the estradiol-induced increase in progesterone receptor levels in a dose-dependent fashion. Insulin-like growth factor-1 (IGF-1) levels in the MCF-7 tumors significantly decreased in the toremifene-alone group as compared with the estradiol-alone group. These results show the antiestrogenic action of toremifene on hormone-dependent MCF-7 tumors in athymic mice.


Estrogen Receptor Estradiol Serum Estradiol Toremifene Athymic Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Campen CA, Jordan VC, Gorski J(1985) Opposing biological action of antiestrogens in vitro and in vivo: induction of progesterone receptor in mouse uterus. Endocrinology 116:2327Google Scholar
  2. 2.
    Dickson RB, McManaway ME, Lippman ME (1986) Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232:1540Google Scholar
  3. 3.
    Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127Google Scholar
  4. 4.
    Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athmic mouce. Cancer Res 48:812Google Scholar
  5. 5.
    Hietanen T, Baltina D, Johansson R, Numminen S, Hakala T, Helle L, Valavaara R (1990) High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res Treat 16 [Suppl]:S37Google Scholar
  6. 6.
    Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer. Role of estradiol and estrogen, Endocrinology 103:1742Google Scholar
  7. 7.
    Iino Y, Ishikawa H, Izuo M, Takikawa H (1989) Sequential hormone therapy with medroxyprogesterone acetate for 7,12-dimethylbenz [a]anthracene-induced rat mammary tumors. Jpn J Clin Oncol 19:45Google Scholar
  8. 8.
    Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC (1991) Reversible control of oestradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse. Br J Cancer 64:1019Google Scholar
  9. 9.
    Jordan VC, Allen KE, Dix CJ (1980) Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745Google Scholar
  10. 10.
    Jordan VC, Fritz NF, Tormey DC (1987) Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on nodepositive patients with breast cancer. Cancer Res 47:624Google Scholar
  11. 11.
    Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perila M, Piippo I, Sundquist H, Soclervall M, Toivola R (1986) A new triphenylethylene compound, Fc-1157a: I.Hormonal effects. Cancer Chemother Pharmacol 17:103Google Scholar
  12. 12.
    Kangan L, Nieminen A-L, Blanco G, Gronroos M, Kallio S, Karjalainen H, Perila M, Sodervall M, Toivola R (1986) A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17:109Google Scholar
  13. 13.
    Kohler PC, Hamm JT, Wiebe VJ, DeGregorio MW, Shemano I, Tormey DC (1990) Phase I study of toremifene and the pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat 16 [Suppl]:S19Google Scholar
  14. 14.
    Koseki Y, Zawa DT, Chamness GC, McGuire WL(1977) Progesterone interaction in the rat uterus: receptor effects. Steroids 30:168Google Scholar
  15. 15.
    Langan-Fahey SM, Tormey DC, Jordan VC (1990) Tamoxifen metabolites in patients on long-term adjuvant tamoxifen therapy for breast cancer. Eur J Cancer 26:883Google Scholar
  16. 16.
    Legha SS, Carter SK (1974) Antiestrogens in the treatment of breast cancer. Cancer Treat Rev 3:205Google Scholar
  17. 17.
    Manni A, Pearson OH (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779Google Scholar
  18. 18.
    Nippon Kayaku Co., Ltd. (1986) Summary of toremifene. Nippon Kayaku Co., Ltd., Tokyo, p 20Google Scholar
  19. 19.
    Osbone CK, Mobbs SK, Clark GM (1985) Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584Google Scholar
  20. 20.
    Pyrhonen SO (1990) Phase III studies of toremlfene in metastatic breast cancer. Breast Cancer Res Treat 16 [Suppl]:S41Google Scholar
  21. 21.
    Robinson SP, Jordan VC (1987) Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 47:5386Google Scholar
  22. 22.
    Robinson SP, Parker CJ, Jordan VC (1990) Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat 16 [Suppl]:S9Google Scholar
  23. 23.
    Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC (1991) Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Dispos Metab 19:36Google Scholar
  24. 24.
    Sawaka CA, Pritchard KI, Paterson AHG, Sutherland DJA, Thomson DB, Shelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW (1986) Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46:3152Google Scholar
  25. 25.
    Valavaara R (1990) Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 [Suppl]:S31Google Scholar
  26. 26.
    Valavaara R, Pyrhonen S, Heikkinen M,Rissanen P, Blanco G, Tholix E, Nordman E, Taskinen P, Holsti L, Hajba A (1988) Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24:785Google Scholar
  27. 27.
    Welshons WV, Jordan VC (1987) Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 23:1935Google Scholar
  28. 28.
    Yee D, Rosen N, Favoni RE, Cullen KJ (1990) The insulin-like growth factors, their receptors and their binding proteins in human breast cancer. In: Lippman ME, Dickson RB (eds) Regulatory mechanisms in breast cancer. Kluwer, Boston, pp 93–106Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Yuchi Iino
    • 1
  • Yoshiki Takai
    • 1
  • Tatsumasa Ando
    • 1
  • Noritaka Sugamata
    • 1
  • Michio Maemura
    • 1
  • Takeshi Takeo
    • 1
  • Susumu Ohwada
    • 1
  • Yasuo Morishita
    • 1
  1. 1.Second Department of SurgeryGunma University School of MedicineMaebashiJapan

Personalised recommendations